Sarah Haessler1, Peter K Lindenauer2,3, Marya D Zilberberg4,5, Peter B Imrey6,7, Pei-Chun Yu6, Tom Higgins8, Abhishek Deshpande9,10, Michael B Rothberg7,9. 1. Division of Infectious Diseases, University of Massachusetts Medical School-Baystate, Springfield, Massachusetts, USA. 2. Institute for Healthcare Delivery and Population Science and Department of Medicine, University of Massachusetts Medical School-Baystate, Springfield, Massachusetts, USA. 3. Department of Quantitative Health Sciences, University of Massachusetts Medical School, Worcester, Massachusetts, USA. 4. EviMed Research Group, LLC, Goshen, Massachusetts, USA. 5. Division of Pulmonary and Critical Medicine, University of Massachusetts School of Public Health and Health Sciences, Amherst, Massachusetts, USA. 6. Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, Ohio, USA. 7. Cleveland Clinic Lerner College of Medicine, Case Western Reserve University, Cleveland, Ohio, USA. 8. Center for Case Management, Natick, Massachusetts, USA. 9. Medicine Institute Center for Value Based Care Research, Medicine Institute, Cleveland Clinic, Cleveland, Ohio, USA. 10. Department of Infectious Diseases, Cleveland Clinic, Cleveland, Ohio, USA.
Abstract
BACKGROUND: Choice of empiric therapy for pneumonia depends on risk for antimicrobial resistance. Models to predict resistance are derived from blood and respiratory culture results. We compared these results to understand if organisms and resistance patterns differed by site. We also compared characteristics and outcomes of patients with positive cultures by site. METHODS: We studied adult patients discharged from 177 US hospitals from July 2010 through June 2015, with principal diagnoses of pneumonia, or principal diagnoses of respiratory failure, acute respiratory distress syndrome, respiratory arrest, or sepsis with a secondary diagnosis of pneumonia, and who had blood or respiratory cultures performed. Demographics, treatment, microbiologic results, and outcomes were examined. RESULTS: Among 138 561 hospitalizations of patients with pneumonia who had blood or respiratory cultures obtained at admission, 12 888 (9.3%) yielded positive cultures: 6438 respiratory cultures, 5992 blood cultures, and 458 both respiratory and blood cultures. Forty-two percent had isolates resistant to first-line therapy for community-acquired pneumonia. Isolates from respiratory samples were more often resistant than were isolates from blood (54.2% vs 26.6%; P < .001). Patients with both culture sites positive had higher case-fatality, longer lengths of stay, and higher costs than patients who had only blood or respiratory cultures positive. Among respiratory cultures, the most common pathogens were Staphylococcus aureus (34%) and Pseudomonas aeruginosa (17%), whereas blood cultures most commonly grew Streptococcus pneumoniae (33%), followed by S. aureus (22%). CONCLUSIONS: Patients with positive respiratory tract cultures are clinically different from those with positive blood cultures, and resistance patterns differ by source. Models of antibiotic resistance should account for culture source.
BACKGROUND: Choice of empiric therapy for pneumonia depends on risk for antimicrobial resistance. Models to predict resistance are derived from blood and respiratory culture results. We compared these results to understand if organisms and resistance patterns differed by site. We also compared characteristics and outcomes of patients with positive cultures by site. METHODS: We studied adult patients discharged from 177 US hospitals from July 2010 through June 2015, with principal diagnoses of pneumonia, or principal diagnoses of respiratory failure, acute respiratory distress syndrome, respiratory arrest, or sepsis with a secondary diagnosis of pneumonia, and who had blood or respiratory cultures performed. Demographics, treatment, microbiologic results, and outcomes were examined. RESULTS: Among 138 561 hospitalizations of patients with pneumonia who had blood or respiratory cultures obtained at admission, 12 888 (9.3%) yielded positive cultures: 6438 respiratory cultures, 5992 blood cultures, and 458 both respiratory and blood cultures. Forty-two percent had isolates resistant to first-line therapy for community-acquired pneumonia. Isolates from respiratory samples were more often resistant than were isolates from blood (54.2% vs 26.6%; P < .001). Patients with both culture sites positive had higher case-fatality, longer lengths of stay, and higher costs than patients who had only blood or respiratory cultures positive. Among respiratory cultures, the most common pathogens were Staphylococcus aureus (34%) and Pseudomonas aeruginosa (17%), whereas blood cultures most commonly grew Streptococcus pneumoniae (33%), followed by S. aureus (22%). CONCLUSIONS:Patients with positive respiratory tract cultures are clinically different from those with positive blood cultures, and resistance patterns differ by source. Models of antibiotic resistance should account for culture source.
Authors: Andre C Kalil; Mark L Metersky; Michael Klompas; John Muscedere; Daniel A Sweeney; Lucy B Palmer; Lena M Napolitano; Naomi P O'Grady; John G Bartlett; Jordi Carratalà; Ali A El Solh; Santiago Ewig; Paul D Fey; Thomas M File; Marcos I Restrepo; Jason A Roberts; Grant W Waterer; Peggy Cruse; Shandra L Knight; Jan L Brozek Journal: Clin Infect Dis Date: 2016-07-14 Impact factor: 9.079
Authors: Andrew F Shorr; Marya D Zilberberg; Richard Reichley; Jason Kan; Alex Hoban; Justin Hoffman; Scott T Micek; Marin H Kollef Journal: Clin Infect Dis Date: 2011-11-21 Impact factor: 9.079
Authors: James D Chalmers; Joanne K Taylor; Aran Singanayagam; Gillian B Fleming; Ahsan R Akram; Pallavi Mandal; Gourab Choudhury; Adam T Hill Journal: Clin Infect Dis Date: 2011-07-15 Impact factor: 9.079
Authors: Peter K Lindenauer; Penelope S Pekow; Maureen C Lahti; Yoojin Lee; Evan M Benjamin; Michael B Rothberg Journal: JAMA Date: 2010-06-16 Impact factor: 56.272
Authors: Alberto Capelastegui; Pedro P España; Amaia Bilbao; Julio Gamazo; Federico Medel; Juan Salgado; Iñaki Gorostiaga; Maria Jose Lopez de Goicoechea; Inmaculada Gorordo; Cristobal Esteban; Lander Altube; Jose M Quintana Journal: BMC Infect Dis Date: 2012-06-12 Impact factor: 3.090
Authors: Michael B Rothberg; Penelope S Pekow; Aruna Priya; Marya D Zilberberg; Raquel Belforti; Daniel Skiest; Tara Lagu; Thomas L Higgins; Peter K Lindenauer Journal: PLoS One Date: 2014-01-31 Impact factor: 3.240
Authors: Richard E Banks; Brigid M Wilson; Taissa Bej; Janet M Briggs; Sunah Song; Michihiko Goto; Robin L P Jump; Federico Perez Journal: Open Forum Infect Dis Date: 2022-02-02 Impact factor: 3.835
Authors: Sarah Haessler; Ning Guo; Abhishek Deshpande; Marya D Zilberberg; Tara Lagu; Peter K Lindenauer; Peter B Imrey; Michael B Rothberg Journal: Crit Care Med Date: 2022-02-22 Impact factor: 9.296
Authors: Marya D Zilberberg; Brian H Nathanson; Laura A Puzniak; Ryan J Dillon; Andrew F Shorr Journal: BMC Infect Dis Date: 2022-10-05 Impact factor: 3.667
Authors: Hannah Lawrence; Harry Pick; Vadsala Baskaran; Priya Daniel; Chamira Rodrigo; Deborah Ashton; Rochelle C Edwards-Pritchard; Carmen Sheppard; Seyi D Eletu; David Litt; Norman K Fry; Samuel Rose; Caroline Trotter; Tricia M McKeever; Wei Shen Lim Journal: PLoS Med Date: 2020-10-23 Impact factor: 11.069